Amedisys Inc (AMED) Earns “Buy” Rating from Jefferies Group LLC

Jefferies Group LLC reiterated their buy rating on shares of Amedisys Inc (NASDAQ:AMED) in a report released on Thursday morning. Jefferies Group LLC currently has a $60.00 price target on the health services provider’s stock.

Several other analysts also recently commented on AMED. BidaskClub downgraded shares of Amedisys from a strong-buy rating to a buy rating in a report on Wednesday, July 12th. Mizuho downgraded shares of Amedisys from a buy rating to a neutral rating and set a $50.00 target price for the company. in a report on Wednesday, July 26th. Bank of America Corporation initiated coverage on shares of Amedisys in a report on Monday, August 21st. They issued a neutral rating and a $55.00 target price for the company. Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $60.00 target price on shares of Amedisys in a report on Friday, September 15th. Finally, Robert W. Baird reiterated a hold rating and issued a $50.00 target price on shares of Amedisys in a report on Wednesday, October 4th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Amedisys has an average rating of Hold and an average target price of $56.20.

Amedisys (AMED) opened at 47.80 on Thursday. The stock has a 50 day moving average of $51.89 and a 200-day moving average of $55.18. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91. The company has a market cap of $1.62 billion, a P/E ratio of 40.85 and a beta of 0.87.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.42 earnings per share. Equities research analysts expect that Amedisys will post $2.21 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Amedisys Inc (AMED) Earns “Buy” Rating from Jefferies Group LLC” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2017/10/16/amedisys-inc-amed-earns-buy-rating-from-jefferies-group-llc.html.

In related news, Director Bruce D. Perkins acquired 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the acquisition, the director now owns 15,825 shares of the company’s stock, valued at approximately $737,445. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now owns 10,488 shares of the company’s stock, valued at approximately $524,400. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Federated Investors Inc. PA increased its holdings in Amedisys by 2.3% during the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after buying an additional 44 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in Amedisys by 0.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock worth $1,235,000 after purchasing an additional 93 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in Amedisys by 1.8% during the first quarter. Municipal Employees Retirement System of Michigan now owns 6,370 shares of the health services provider’s stock worth $325,000 after purchasing an additional 110 shares during the period. Arizona State Retirement System boosted its position in Amedisys by 1.4% during the first quarter. Arizona State Retirement System now owns 14,550 shares of the health services provider’s stock worth $743,000 after purchasing an additional 200 shares during the period. Finally, Suntrust Banks Inc. boosted its position in Amedisys by 4.3% during the second quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock worth $358,000 after purchasing an additional 237 shares during the period. Institutional investors and hedge funds own 96.55% of the compa

Several other analysts also recently commented on AMED. BidaskClub downgraded shares of Amedisys from a strong-buy rating to a buy rating in a report on Wednesday, July 12th. Mizuho downgraded shares of Amedisys from a buy rating to a neutral rating and set a $50.00 target price for the company. in a report on Wednesday, July 26th. Bank of America Corporation initiated coverage on shares of Amedisys in a report on Monday, August 21st. They issued a neutral rating and a $55.00 target price for the company. Oppenheimer Holdings, Inc. reiterated a buy rating and issued a $60.00 target price on shares of Amedisys in a report on Friday, September 15th. Finally, Robert W. Baird reiterated a hold rating and issued a $50.00 target price on shares of Amedisys in a report on Wednesday, October 4th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Amedisys has an average rating of Hold and an average target price of $56.20.

Amedisys (AMED) opened at 47.80 on Thursday. The stock has a 50 day moving average of $51.89 and a 200-day moving average of $55.18. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91. The company has a market cap of $1.62 billion, a P/E ratio of 40.85 and a beta of 0.87.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.42 earnings per share. Equities research analysts expect that Amedisys will post $2.21 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Amedisys Inc (AMED) Earns “Buy” Rating from Jefferies Group LLC” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://ledgergazette.com/2017/10/16/amedisys-inc-amed-earns-buy-rating-from-jefferies-group-llc.html.

In related news, Director Bruce D. Perkins acquired 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the completion of the acquisition, the director now owns 15,825 shares of the company’s stock, valued at approximately $737,445. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the sale, the insider now owns 10,488 shares of the company’s stock, valued at approximately $524,400. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Federated Investors Inc. PA increased its holdings in Amedisys by 2.3% during the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after buying an additional 44 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in Amedisys by 0.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock worth $1,235,000 after purchasing an additional 93 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in Amedisys by 1.8% during the first quarter. Municipal Employees Retirement System of Michigan now owns 6,370 shares of the health services provider’s stock worth $325,000 after purchasing an additional 110 shares during the period. Arizona State Retirement System boosted its position in Amedisys by 1.4% during the first quarter. Arizona State Retirement System now owns 14,550 shares of the health services provider’s stock worth $743,000 after purchasing an additional 200 shares during the period. Finally, Suntrust Banks Inc. boosted its position in Amedisys by 4.3% during the second quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock worth $358,000 after purchasing an additional 237 shares during the period. Institutional investors and hedge funds own 96.55% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply